Finanzen von Attovia Therapeutics Inc (ATTO)ATTOAttovia Therapeutics Inc

Evaluating the bottom line, Attovia Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4845.11%, while the net margin is -4597.11%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ATTO converts its operational activities into shareholder value.

In the context of the broader market, ATTO competes directly with industry leaders such as SLDB and WVE. With a market capitalization of $626.79M, it holds a significant position in the sector. When comparing efficiency, ATTO's gross margin of 100.00% stands against SLDB's N/A and WVE's 100.00%. Such benchmarking helps identify whether Attovia Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported zero revenue in Q1 2026 and a modest revenue of $450,000 in Q2 2026, indicating a lack of consistent income generation. The net income for Q2 2026 was a loss of $20.69 million, further highlighting financial challenges.